Cross-reactivity of commercial immunoassays for screening of new amphetamine designer drugs. A review.

The chemical modification of the molecular structure of psychoactive substances is a very common practice in the illicit drugs market, to by-pass current regulations; this lead to the production of compounds, known as "designer drugs", with the same or greater pharmacological effects of the parent drug. The phenomenon is also favored by the fact that the new synthetic compounds are not considered illegal by existing legislation. Amphetamine derivatives represent one of the largest classes of designer drugs. Generally, in toxicological laboratories, rapid screening tests are used for a first monitoring of drugs abuse. However, the available immunoassays for this class of substances are designed for amphetamine, methamphetamine and methylenedioxymethamphetamine, and generally they are unable to detect various amphetamine analogues. This can constitute a disadvantage because it can generate a great number of false-negative results. The present review aims to provide an overview of the cross-reactivity studies carried out on commercially available immunoassays to identify the presence of amphetamine derivatives in biological samples. The knowledge of cross-reactivity data makes it easier to interpret analytical results by demonstrating that a negative result does not always indicate the non-consumption of an amphetamine derivative. This review highlights the great need for more comprehensive screening immunoassays to use when analyzing biological matrices for drugs of abuse search, specifically for the more recent designer drugs..

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.